logo

2 GRANTS FROM CENTRO PARA EL DESARROLLO TECNOLÓGICO Y LA INNOVACIÓN

2 GRANTS FROM CENTRO PARA EL DESARROLLO TECNOLÓGICO Y LA INNOVACIÓN

Leave a Comment / Uncategorized / By

The Administration Board of the Centro para el Desarrollo Tecnológico y la Innovación, E.P.E (CDTI), has approved 2 important grants for Moehs Group:

  1. ABROCITINIB: development of a new chemical synthesis method of a janus kinase inhibitor active ingredient for the treatment of atopic dermatitis.
  2. VERICIGUAT: the objective is to develop a new method of chemical synthesis of a soluble guanylate cyclase stimulator active substance.

The Moehs team is already fully available to meet the needs and specifications of our customers.

The execution period is from 2022 to 2025 and this project is co-funded by the European Union and CDTI.

 

 

 

 

 

 

 

Leave a Comment

Your email address will not be published. Required fields are marked *

logo
Twitter Linkedin-in
  • Headquarters:
  • Pol. Ind. Cova Solera
  • c/Roma, 8-12 08191 Rubí.
  • Barcelona (Spain)
  • T +34 93 586 05 20
  • Fax +34 93 588 85 13
  • info@moehs.es

Partnering companies

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF A STIMULATOR ACTIVE PRINCIPLE OF SOLUBLE CYCLASE GUANYLATE by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of an active ingredient that stimulates soluble guanylate cyclase.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2024 and they have a financeable budget of €1,862,213.00.
This project is co-financed by the European Union and CDTI.

The Board of Directors of the Center for Technological Development and Innovation, E.P.E (CDTI), in its meeting held on 02/23/2023, approved the participation of this center in the research and development project called SYNTHESIS OF AN ACTIVE INHIBITOR PRINCIPLE OF JANUS KINASE FOR THE TREATMENT OF ATOPIC DERMATITIS.”, by granting partially reimbursable aid.

The objective is focused on the development of a new method of chemical synthesis of a janus kinase inhibitor active ingredient for the treatment of atopic dermatitis.

The project will be carried out at the Rubí facilities. The project execution period is from 2022 to 2025 and they have a financeable budget of €1,940,409.
This project is co-financed by the European Union and CDTI.